Sunshine Biopharma (SBFM) Cash from Financing Activities (2010 - 2026)
Sunshine Biopharma's (SBFM) quarterly Cash from Financing Activities came in at $724500.0 in Q4 2025, down 55.23% YoY from $1.6 million in Q4 2024, and up 859.15% on a QoQ basis from $75536.0 in Q3 2025.
Sunshine Biopharma (SBFM) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Sunshine Biopharma (SBFM) has 16 years of Cash from Financing Activities data on file, last reported at $724500.0 in Q4 2025.
- Quarterly Cash from Financing Activities fell 55.23% year-over-year to $724500.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $4.4 million (up 12.68% YoY) and the FY2025 annual result came in at $4.7 million, down 46.9% from the prior year.
- Cash from Financing Activities advanced to $724500.0 in Q4 2025, from $75536.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $29.1 million in Q2 2022 to a low of -$2.1 million in Q4 2022.
- A 5-year average of $3.1 million and a median of $724500.0 in 2025 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 8758.42% — and 2025, when it jumped 12670.67%.
- Tracing SBFM's Cash from Financing Activities over 5 years: stood at -$23664.0 in 2021, then slumped by 8758.42% to -$2.1 million in 2022, then surged by 98.54% to -$30519.0 in 2023, then surged by 5402.28% to $1.6 million in 2024, then slumped by 55.23% to $724500.0 in 2025.
- The last three Cash from Financing Activities figures came in at $724500.0 (Q4 2025), $75536.0 (Q3 2025), and $3.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Sunshine Biopharma | 1.58 Mn | -12.17 Mn | 2.43 Mn | 7.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.80 Mn |
| Jun 30, 2026 | 7.80 Mn |
| Dec 31, 2025 | 724,500.00 |
| Dec 31, 2025 | 724,500.00 |
| Sep 30, 2025 | 75,536.00 |
| Sep 30, 2025 | 75,536.00 |
| Jun 30, 2025 | 3.59 Mn |
| Jun 30, 2025 | 3.59 Mn |
| Mar 31, 2025 | 355,297.00 |
| Mar 31, 2025 | 355,297.00 |
| Dec 31, 2024 | 1.62 Mn |
| Dec 31, 2024 | 1.62 Mn |
| Sep 30, 2024 | 1.95 Mn |
| Sep 30, 2024 | 1.95 Mn |
| Jun 30, 2024 | -28,583.00 |
| Jun 30, 2024 | -28,583.00 |
| Mar 31, 2024 | 5.40 Mn |
| Mar 31, 2024 | 5.40 Mn |
| Dec 31, 2023 | -30,519.00 |
| Dec 31, 2023 | -30,519.00 |